Skip to content
Epsilogen
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
    • Advisers
  • Why IgE?
  • MOv18 IgE
  • IgEG Platform
  • News
    • Recent News
    • Publications
  • Recruitment
  • Contact

Category: Articles

Novartis backs Epsilogen’s bid to turn ‘Cinderella antibody’ into new class of cancer drug | Fierce Biotech

This article appeared in Fierce Biotech, March 2 2022

See the article in full here

Epsilogen raises £30.8M series B to support testing IgE antibody against ovarian cancer | BioWorld

 

Epsilogen Ltd was profiled in BioWorld  on March 2, 2022.

See the article in full here

Epsilogen’s CEO speaks to Lu Rahman about their ongoing work in developing novel IgE antibodies to treat cancer.

This article first appeared in Drug Discovery World, Spring 2021, Volume 22, Issue 2.

   

See the article in full here

BioCentury

Epsilogen: co-opting IgE antibodies against cancer

Epsilogen Ltd was profiled in BioCentury’s Emerging Company Profile on June 5, 2020.

See the article in full here

IGEM Therapeutics: Pursuing Novel IgE Antibodies For Solid Tumors

Emerging Company Profile: IGEM Therapeutics has been spun out of King’s College London to evaluate the use of IgE-based monoclonal antibodies for the treatment of cancer, including difficult-to-reach solid tumors….

…..

See the article in full here: https://scrip.pharmaintelligence.informa.com/SC123214/IGEM-Therapeutics-Pursuing-Novel-IgE-Antibodies-For-Solid-Tumors

Genetic Engineering News Article

Not to be Sneezed At

One of the stand-out technologies discussed by London-based immuno-oncology start-up Epsilogen was in antibody therapeutics…..

See the article in full here:  https://www.genengnews.com/gen-exclusives/biotrinity-conference-focuses-on-nextgen-healthcare/77901102

Recent Posts

  • Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer
  • Epsilogen announces significant expansion of management team with three new senior hires
  • Epsilogen announces completion of oversubscribed £30.75 million ($41.20 million) Series B financing
  • Novartis backs Epsilogen’s bid to turn ‘Cinderella antibody’ into new class of cancer drug | Fierce Biotech
  • Epsilogen raises £30.8M series B to support testing IgE antibody against ovarian cancer | BioWorld

Recent Comments

  1. A WordPress Commenter on Nature Article Cites IgE Antibodies as a Technology to Watch in 2021 and Notes their Potential as an Anti-Cancer Therapy

Archives

  • July 2023
  • April 2023
  • March 2022
  • April 2021
  • February 2021
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • April 2020
  • April 2019
  • November 2018
  • October 2018
  • August 2018
  • June 2018
  • May 2018
  • April 2018
  • August 2017

Categories

  • Articles
  • Events
  • IGEM in the News
  • Press Release
  • Press Releases

Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer.

Contact Us

+44 (0)203 657 7612
General Enquiries
Interested in joining Epsilogen?

Menu

  • About Us
  • Why IgE?
  • MOv18 IgE
  • IgEG Platform
  • Recent News
  • Recruitment
Find us on Google Maps
  • Epsilogen Ltd © 2023
  • All Rights Reserved
  • Terms of Use
  • Privacy Policy
designed by Kehorne

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!